YU66100A - N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat - Google Patents

N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat

Info

Publication number
YU66100A
YU66100A YU66100A YU66100A YU66100A YU 66100 A YU66100 A YU 66100A YU 66100 A YU66100 A YU 66100A YU 66100 A YU66100 A YU 66100A YU 66100 A YU66100 A YU 66100A
Authority
YU
Yugoslavia
Prior art keywords
methoxyethoxy
bis
ethynylphenylamino
monohydrate
quinazolinamine mesylate
Prior art date
Application number
YU66100A
Other languages
English (en)
Inventor
John Meldrum Douglas
Timothy Norris
William Jeffrey Raggon
Paul Dinos Santafianos
Mysore Ravi Shanker
Original Assignee
Osi Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals Inc. filed Critical Osi Pharmaceuticals Inc.
Publication of YU66100A publication Critical patent/YU66100A/sh
Publication of RS50081B publication Critical patent/RS50081B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ovaj pronalazak se odnosi na anhidrovane i hidratisane oblike N-(3-etinilfenil)-6,7-bis(2-metoksietoksi)-4-hinazolinamin mezilata. Ovaj pronalazak se takodje odnosi i na farmaceutske preparate koji sadrže N-(3-etinilfenil)-6,7-bis(2-meoksietoksi)-4-hinazolinamin mezilat i na upotrebu anhidrovanog ili hidratisanog oblika N-(3-etinilfenil)-6,7-bis(2-metoksietoksi)-4-hinazolinamin mezilata za proizvodnju leka korisnog u lečenju hiperproliferativnog obljenja kod sisara.[The present invention relates to the anhydrous and hydrate forms of N- (3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)4- quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N- (3-ethynylphenyl)-6,7-bis(2- methoxyethoxy) -4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N- (3-ethynylphenyl)-6,7- bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
YUP-661/00A 1998-04-29 1999-04-08 N-(3-etinilfenilamino)-6,7-bis (2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat RS50081B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (2)

Publication Number Publication Date
YU66100A true YU66100A (sh) 2003-07-07
RS50081B RS50081B (sr) 2009-01-22

Family

ID=22178359

Country Status (42)

Country Link
EP (1) EP1076652B1 (sh)
JP (1) JP4652569B2 (sh)
KR (1) KR100668412B1 (sh)
CN (2) CN1298396A (sh)
AP (1) AP1252A (sh)
AR (1) AR018201A1 (sh)
AT (1) ATE295839T1 (sh)
AU (1) AU759691C (sh)
BR (1) BR9910025A (sh)
CA (1) CA2330447C (sh)
CO (1) CO5060467A1 (sh)
CZ (1) CZ298230B6 (sh)
DE (1) DE69925366T2 (sh)
DZ (1) DZ2777A1 (sh)
EA (1) EA002836B1 (sh)
EG (1) EG24000A (sh)
ES (1) ES2238825T3 (sh)
GT (1) GT199900063A (sh)
HK (1) HK1037180A1 (sh)
HN (1) HN1999000057A (sh)
HU (1) HU227569B1 (sh)
ID (1) ID27198A (sh)
IL (1) IL139172A0 (sh)
MA (1) MA26624A1 (sh)
ME (1) MEP42008A (sh)
MX (1) MXPA00010610A (sh)
MY (1) MY136033A (sh)
NO (1) NO317301B1 (sh)
NZ (1) NZ508154A (sh)
OA (1) OA11769A (sh)
PA (1) PA8471001A1 (sh)
PE (1) PE20000441A1 (sh)
PL (1) PL196940B1 (sh)
RS (1) RS50081B (sh)
SA (1) SA99200216B1 (sh)
TN (1) TNSN99079A1 (sh)
TR (1) TR200003166T2 (sh)
TW (1) TWI248437B (sh)
UA (1) UA60363C2 (sh)
UY (1) UY26099A1 (sh)
WO (1) WO1999055683A1 (sh)
ZA (1) ZA992972B (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
PL1680426T3 (pl) 2003-06-10 2008-02-29 Hoffmann La Roche Pochodne 1,3,4-triazafenalenu i 1,3,4,6-tetraazafenalenu
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
CA2593084C (en) 2004-12-30 2014-03-18 Bioresponse, Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
US8642758B2 (en) * 2007-04-04 2014-02-04 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
ES2492645T3 (es) 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
US20100136116A1 (en) 2007-08-17 2010-06-03 Hetero Drugs Limited Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PT817775E (pt) * 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
MA26624A1 (fr) 2004-12-20
TR200003166T2 (tr) 2001-02-21
CZ20003974A3 (en) 2001-05-16
EG24000A (en) 2008-03-19
MY136033A (en) 2008-07-31
EP1076652A1 (en) 2001-02-21
EA002836B1 (ru) 2002-10-31
AU759691C (en) 2004-04-29
HUP0101818A3 (en) 2002-05-28
KR100668412B1 (ko) 2007-01-12
NO20005453D0 (no) 2000-10-27
CN101219999A (zh) 2008-07-16
BR9910025A (pt) 2000-12-26
AR018201A1 (es) 2001-10-31
DE69925366D1 (de) 2005-06-23
TNSN99079A1 (fr) 2005-11-10
UA60363C2 (uk) 2003-10-15
CA2330447A1 (en) 1999-11-04
PL196940B1 (pl) 2008-02-29
EP1076652B1 (en) 2005-05-18
SA99200216B1 (ar) 2006-06-04
ES2238825T3 (es) 2005-09-01
OA11769A (en) 2005-07-25
UY26099A1 (es) 2001-12-28
IL139172A0 (en) 2001-11-25
HUP0101818A1 (hu) 2002-03-28
GT199900063A (es) 2000-10-20
PL343766A1 (en) 2001-09-10
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
JP4652569B2 (ja) 2011-03-16
ID27198A (id) 2001-03-08
HK1037180A1 (en) 2002-02-01
CO5060467A1 (es) 2001-07-30
AP9901523A0 (en) 1999-06-30
CN1298396A (zh) 2001-06-06
AU2850999A (en) 1999-11-16
ZA992972B (en) 2000-10-30
KR20010078710A (ko) 2001-08-21
NZ508154A (en) 2003-07-25
CA2330447C (en) 2009-06-30
MXPA00010610A (es) 2002-07-02
EA200001112A1 (ru) 2001-04-23
AU759691B2 (en) 2003-04-17
AP1252A (en) 2004-02-25
HN1999000057A (es) 1999-09-29
WO1999055683A1 (en) 1999-11-04
PE20000441A1 (es) 2000-05-23
RS50081B (sr) 2009-01-22
JP2002513009A (ja) 2002-05-08
NO317301B1 (no) 2004-10-04
ATE295839T1 (de) 2005-06-15
TWI248437B (en) 2006-02-01
MEP42008A (en) 2011-02-10
NO20005453L (no) 2000-12-20
CZ298230B6 (cs) 2007-08-01
PA8471001A1 (es) 2000-09-29
HU227569B1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
YU66100A (sh) N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
YU34202A (sh) Stabilni polimorf n-(3-etinilfenilamino)-6,7-bis(2- metoksietoksi)-4-kvinazolinamin hidrohlorida, postupci proizvodnje i njegova farmaceutska upotreba
MXPA04004219A (es) Derivados de quinazolina como agentes antitumorales.
HK1091486A1 (en) Quinazoline derivatives
MXPA05007831A (es) Preparacion de quinazolinas substituidas.
HRP20050707A2 (en) Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)
MXPA04004220A (es) Derivados de quinazolina como agentes antitumorales.
AP2004003058A0 (en) Quinazoline derivatives for the treatment of abnormal cell growth.
RS20050441A (en) C-6 modified indazolylpyrroltriazines
MY138851A (en) Quinazoline derivatives
HK1087613A1 (en) Quinazoline derivatives and their use in the treatment of cancer
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
UA84167C2 (ru) Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
PL367682A1 (en) Dolastatin 10 derivatives
AP2004003059A0 (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA05000781A (es) Compuesto antitumor y usos terapeuticos del mismo.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
MXPA06003161A (es) Derivados de quinazolina.
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
BRPI0411126A (pt) derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
TH52877A3 (th) N-(3-เอททินิลฟีนิลามิโน)-6,7-บิส(2-เมททอกซีเอททอกซี)-4-ควินาโซลินเอมีนเมซิเลตแอนไฮเดรตและโมโนไฮเดรต